Kathryn Gold, MD, UC San Diego Health

home / authors / kathryn-gold-md-uc-san-diego-health

Articles

Kathryn A. Gold, MD

Dr. Gold on Current Unmet Needs in Squamous Cell Carcinoma of the Lung

Kathryn Gold, MD, UC San Diego Health
December 23rd 2021

Kathryn A. Gold, MD, medical oncologist, professor of medicine, UC San Diego Health, discusses current unmet needs in squamous cell carcinoma of the lung.

Read More

Ongoing Research in Extensive-Stage Small Cell Lung Cancer

Ongoing Research in Extensive-Stage Small Cell Lung Cancer

Kathryn Gold, MD, UC San Diego Health;Konstantinos Leventakos, MD, PhD Mayo Clinic ;Taofeek K. Owonikoko, MD, PhD; UPMC Hillman Cancer Center
December 11th 2020

Read More

Treatment After Progression on Front-Line Therapy in Extensive-Stage Small Cell Lung Cancer

Treatment After Progression on Front-Line Therapy in Extensive-Stage Small Cell Lung Cancer

Kathryn Gold, MD, UC San Diego Health;Konstantinos Leventakos, MD, PhD Mayo Clinic ;Taofeek K. Owonikoko, MD, PhD; UPMC Hillman Cancer Center
December 11th 2020

Read More

First-Line Approach for Treating Extensive-Stage Small Cell Lung Cancer

First-Line Approach for Treating Extensive-Stage Small Cell Lung Cancer

Kathryn Gold, MD, UC San Diego Health;Konstantinos Leventakos, MD, PhD Mayo Clinic ;Taofeek K. Owonikoko, MD, PhD; UPMC Hillman Cancer Center
December 11th 2020

Read More

Results from the CASPIAN Trial for Extensive-Stage Small Cell Lung Cancer

Results from the CASPIAN Trial for Extensive-Stage Small Cell Lung Cancer

Kathryn Gold, MD, UC San Diego Health;Konstantinos Leventakos, MD, PhD Mayo Clinic ;Taofeek K. Owonikoko, MD, PhD; UPMC Hillman Cancer Center
December 11th 2020

Read More

Results from the IMpower133 Trial for Extensive-Stage Small Cell Lung Cancer

Results from the IMpower133 Trial for Extensive-Stage Small Cell Lung Cancer

Kathryn Gold, MD, UC San Diego Health;Konstantinos Leventakos, MD, PhD Mayo Clinic ;Taofeek K. Owonikoko, MD, PhD; UPMC Hillman Cancer Center
December 11th 2020

Read More

Advances in Extensive-Stage Small Cell Lung Cancer

Advances in Extensive-Stage Small Cell Lung Cancer

Kathryn Gold, MD, UC San Diego Health;Konstantinos Leventakos, MD, PhD Mayo Clinic ;Taofeek K. Owonikoko, MD, PhD; UPMC Hillman Cancer Center
December 11th 2020

Read More

Rationale for I/O therapy in Extensive-Stage Small Cell Lung Cancer

Rationale for I/O therapy in Extensive-Stage Small Cell Lung Cancer

Kathryn Gold, MD, UC San Diego Health;Konstantinos Leventakos, MD, PhD Mayo Clinic ;Taofeek K. Owonikoko, MD, PhD; UPMC Hillman Cancer Center
December 11th 2020

Read More

Aggressive Nature of Extensive-Stage Small Cell Lung Cancer

Aggressive Nature of Extensive-Stage Small Cell Lung Cancer

Kathryn Gold, MD, UC San Diego Health;Konstantinos Leventakos, MD, PhD Mayo Clinic ;Taofeek K. Owonikoko, MD, PhD; UPMC Hillman Cancer Center
December 11th 2020

Read More

Differentiating Small Cell Lung Cancer and Non-Small Cell Lung Cancer

Differentiating Small Cell Lung Cancer and Non-Small Cell Lung Cancer

Kathryn Gold, MD, UC San Diego Health;Konstantinos Leventakos, MD, PhD Mayo Clinic ;Taofeek K. Owonikoko, MD, PhD; UPMC Hillman Cancer Center
December 11th 2020

Read More

Background of Small Cell Lung Cancer

Background of Small Cell Lung Cancer

Kathryn Gold, MD, UC San Diego Health;Konstantinos Leventakos, MD, PhD Mayo Clinic ;Taofeek K. Owonikoko, MD, PhD; UPMC Hillman Cancer Center
December 11th 2020

Read More

Latest Updated Articles

Phase 1/2 ALKOVE-1 study of NVL-655 in ALK-positive (ALK+) solid tumors
Published: October 30th 2024 | Updated: November 7th 2024
Phase 1/2 ALKOVE-1 Study of NVL-655 in ALK-positive (ALK+) Solid Tumors
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Published: October 18th 2024 | Updated: October 21st 2024
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Published: October 14th 2024 | Updated: October 16th 2024
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Phase 1 trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3 Positive Tumors: Patients with LCNEC
Published: September 27th 2024 | Updated: October 9th 2024
Petosemtamab Plus Pembrolizumab vs. Pembrolizumab Alone for First-Line (1L) Treatment of Recurrent/Metastatic (R/M) PD-L1–Positive Head and Neck Squamous Cell Carcinoma (HNSCC): A Randomized, Open-Label, Phase 3 Trial
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Published: September 30th 2024 | Updated: October 4th 2024
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Real world evidence of treatment practices and therapeutic outcomes for newly diagnosed NSCLC patients with non-classical EGFR mutations demonstrates high unmet medical need
Published: September 27th 2024 | Updated: October 4th 2024
Real World Evidence of Treatment Practices and Therapeutic Outcomes for Newly Diagnosed NSCLC Patients With Non-Classical EGFR Mutations Demonstrates High Unmet Medical Need